Kenneth Pienta


1981 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Kenneth Pienta is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Prostatic Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences
Prostate Medicine & Life Sciences
Androgens Medicine & Life Sciences
Hormones Medicine & Life Sciences
Bone and Bones Medicine & Life Sciences
Estramustine Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1981 2019

AXL is a putative tumor suppressor and dormancy regulator in prostate cancer

Axelrod, H. D., Valkenburg, K. C., Amend, S., Hicks, J. L., Parsana, P., Torga, G., Demarzo, A. M. & Pienta, K., Feb 1 2019, In : Molecular Cancer Research. 17, 2, p. 356-369 14 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Bone Marrow
Neoplasm Metastasis
Bone Neoplasms
Theranostic Nanomedicine

Computational modeling of the crosstalk between macrophage polarization and tumor cell plasticity in the tumor microenvironment

Li, X., Jolly, M. K., George, J. T., Pienta, K. & Levine, H., Jan 1 2019, In : Frontiers in Oncology. 9, JAN, 10.

Research output: Contribution to journalArticle

Open Access
Tumor Microenvironment
Cell Plasticity
Coculture Techniques

Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer

Cackowski, F. C., Wang, Y., Decker, J. T., Sifuentes, C., Weindorf, S., Jung, Y., Wang, Y., Decker, A. M., Yumoto, K., Szerlip, N., Buttitta, L., Pienta, K., Morgan, T. M. & Taichman, R. S., Jan 1 2019, In : Prostate. 79, 14, p. 1715-1727 13 p.

Research output: Contribution to journalArticle

Bone Marrow Cells
Prostatic Neoplasms
RNA Sequence Analysis

Evaluation of intense androgen deprivation before prostatectomy: A randomized Phase II trial of enzalutamide and leuprolide with or without abiraterone

McKay, R. R., Ye, H., Xie, W., Lis, R., Calagua, C., Zhang, Z., Trinh, Q. D., Chang, S. L., Harshman, L. C., Ross, A. E., Pienta, K., Lin, D. W., Ellis, W. J., Montgomery, B., Chang, P., Wagner, A. A., Bubley, G. J., Kibel, A. S. & Taplin, M. E., Jan 1 2019, In : Journal of Clinical Oncology. 37, 11, p. 923-931 9 p.

Research output: Contribution to journalArticle

Residual Neoplasm
Prostate-Specific Antigen